Bimzelx (bimekizumab-bkzx) — Medica

Initial criteria

• age > 18 years
• evaluated for risks of suicidal ideation or behavior versus benefits of therapy
• no moderately severe to severe depression
• no history of suicidal ideation or behavior within the past 5 years
• prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• established on therapy for at least 6 months
• evaluated for risks of suicidal ideation or behavior versus benefits of therapy
• no moderately severe to severe depression
• no suicidal ideation or suicidal behavior
• beneficial clinical response by at least one objective measure OR improvement in at least one symptom compared with baseline

Approval duration

initial 6 months, reauth 1 year